(3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
| Title | Journal |
|---|---|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. | Journal of medicinal chemistry 20140424 |
| High fat diet and GLP-1 drugs induce pancreatic injury in mice. | Toxicology and applied pharmacology 20140415 |
| Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations. | Journal of molecular modeling 20140401 |
| Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes. | ACS medicinal chemistry letters 20130808 |
| Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats. | Chemico-biological interactions 20130425 |
| A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. | European journal of pharmacology 20121205 |
| Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201 |
| Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201 |
| Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. | Regulatory peptides 20121110 |
| Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. | Journal of clinical pharmacology 20121001 |
| Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20121001 |
| Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. | Diabetes, obesity & metabolism 20121001 |
| No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. | Diabetes, obesity & metabolism 20121001 |
| Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. | Diabetes research and clinical practice 20121001 |
| Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. | Diabetes care 20121001 |
| Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? | Diabetes technology & therapeutics 20121001 |
| Recent advances in incretin-based therapies. | Clinical endocrinology 20121001 |
| Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. | Diabetes & metabolism 20121001 |
| Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. | Bioorganic & medicinal chemistry 20121001 |
| Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. | Journal of clinical medicine research 20121001 |
| Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. | Journal of cardiac failure 20121001 |
| Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. | Advances in therapy 20121001 |
| Linagliptin as add-on therapy for type 2 diabetes - an overview. | Drugs of today (Barcelona, Spain : 1998) 20121001 |
| Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. | Diabetes, obesity & metabolism 20120901 |
| Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. | Diabetes, obesity & metabolism 20120901 |
| The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. | Journal of diabetes 20120901 |
| Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. | Diabetologia 20120901 |
| Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease. | Naunyn-Schmiedeberg's archives of pharmacology 20120901 |
| Sitagliptin exerts an antinflammatory action. | The Journal of clinical endocrinology and metabolism 20120901 |
| Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. | Hypertension (Dallas, Tex. : 1979) 20120901 |
| Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. | Hypertension (Dallas, Tex. : 1979) 20120901 |
| [Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction]. | MMW Fortschritte der Medizin 20120823 |
| Exenatide extended-release: a review of its use in type 2 diabetes mellitus. | Drugs 20120820 |
| Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. | Clinical endocrinology 20120801 |
| Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. | The Journal of dermatology 20120801 |
| Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. | Diabetes, obesity & metabolism 20120801 |
| GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. | Current clinical pharmacology 20120801 |
| Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. | Diabetes, obesity & metabolism 20120801 |
| Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. | Diabetologia 20120801 |
| Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20120801 |
| Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. | Clinical pharmacokinetics 20120801 |
| Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. | Current medical research and opinion 20120801 |
| The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. | Alimentary pharmacology & therapeutics 20120801 |
| Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. | Current medical research and opinion 20120801 |
| Mechanism of action of DPP-4 inhibitors--new insights. | The Journal of clinical endocrinology and metabolism 20120801 |
| Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. | Journal of clinical medicine research 20120801 |
| Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. | Diabetes, obesity & metabolism 20120701 |
| Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. | Diabetes, obesity & metabolism 20120701 |
| The pancreatic beta cell surface proteome. | Diabetologia 20120701 |
| The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. | Diabetes technology & therapeutics 20120701 |
| Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. | Current medical research and opinion 20120701 |
| The incretin hormones: from scientific discovery to practical therapeutics. | Diabetologia 20120701 |
| Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. | Current medical research and opinion 20120701 |
| Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs. | Journal of clinical hypertension (Greenwich, Conn.) 20120701 |
| [Liraglutide: new results in the treatment of type 2 diabetes mellitus]. | Drugs of today (Barcelona, Spain : 1998) 20120701 |
| Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. | Lancet (London, England) 20120616 |
| Choosing a blood-glucose-lowering agent after metformin. | Lancet (London, England) 20120616 |
| Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120615 |
| Sitagliptin counteracts seasonal fluctuation of glycemic control. | World journal of diabetes 20120615 |
| Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation. | Journal of medicinal chemistry 20120614 |
| [Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China]. | Zhonghua yi xue za zhi 20120612 |
| Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. | Acta diabetologica 20120601 |
| Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. | Diabetes, obesity & metabolism 20120601 |
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. | Diabetes care 20120601 |
| Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. | Expert opinion on drug metabolism & toxicology 20120601 |
| Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. | Acta gastro-enterologica Belgica 20120601 |
| Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. | Bioorganic & medicinal chemistry letters 20120515 |
| Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. | Diabetic medicine : a journal of the British Diabetic Association 20120501 |
| Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20120501 |
| Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. | Diabetes, obesity & metabolism 20120501 |
| Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. | European journal of clinical pharmacology 20120501 |
| Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms. | Diabetes/metabolism research and reviews 20120501 |
| An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. | Current diabetes reviews 20120501 |
| High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501 |
| Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. | International journal of clinical practice 20120501 |
| Prediction of drug-target interactions and drug repositioning via network-based inference. | PLoS computational biology 20120501 |
| Immunotherapies in diabetes mellitus type 1. | The Medical clinics of North America 20120501 |
| Association between sitagliptin adherence and self-monitoring of blood glucose. | Journal of diabetes science and technology 20120501 |
| Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin. | Chinese medical journal 20120501 |
| The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. | American journal of physiology. Gastrointestinal and liver physiology 20120415 |
| DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. | Diabetes & metabolism 20120401 |
| Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. | Neurobiology of disease 20120401 |
| Dipeptidyl peptidase-4 inhibitors: 3 years of experience. | Diabetes technology & therapeutics 20120401 |
| The design of the liraglutide clinical trial programme. | Diabetes, obesity & metabolism 20120401 |
| Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. | Diabetes, obesity & metabolism 20120401 |
| Liraglutide: from clinical trials to clinical practice. | Diabetes, obesity & metabolism 20120401 |
| Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. | Diabetic medicine : a journal of the British Diabetic Association 20120301 |
| Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. | The Annals of pharmacotherapy 20120301 |
| Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide. | Minerva endocrinologica 20120301 |
| Pleiotropic effects of incretins. | Indian journal of endocrinology and metabolism 20120301 |
| Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. | The Journal of the Association of Physicians of India 20120301 |
| Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. | Oncogene 20120223 |
| The importance of green chemistry in process research and development. | Chemical Society reviews 20120221 |
| Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®). | Dermatology online journal 20120215 |
| Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. | Journal of the European Academy of Dermatology and Venereology : JEADV 20120201 |
| Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. | Cancer chemotherapy and pharmacology 20120201 |
| Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. | Diabetes research and clinical practice 20120201 |
| Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning. | Experimental hematology 20120201 |
| Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. | Endocrinology 20120201 |
| Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. | Diabetes care 20120201 |
| Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor. | The Australasian journal of dermatology 20120201 |
| Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. | Drugs 20120122 |
| A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. | Journal of the American College of Cardiology 20120117 |
| Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. | Journal of the American College of Cardiology 20120117 |
| Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. | Diabetes, obesity & metabolism 20120101 |
| Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing. | Journal of nephrology 20120101 |
| Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. | European journal of heart failure 20120101 |
| Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20120101 |
| The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. | Diabetes research and clinical practice 20120101 |
| Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. | Dermatology (Basel, Switzerland) 20120101 |
| Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101 |
| Diabetes: impaired damage control. | Diabetologia 20120101 |
| Why do metabolites circulate? | Xenobiotica; the fate of foreign compounds in biological systems 20120101 |
| Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. | Acta pharmacologica Sinica 20120101 |
| A review of gliptins in 2011. | Expert opinion on pharmacotherapy 20120101 |
| Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. | Translational research : the journal of laboratory and clinical medicine 20120101 |
| Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. | Hepato-gastroenterology 20120101 |
| Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. | Endocrine journal 20120101 |
| Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. | Basic research in cardiology 20120101 |
| [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101 |
| DPP-4 inhibitors and lipids: systematic review and meta-analysis. | Advances in therapy 20120101 |
| Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. | Cardiovascular diabetology 20120101 |
| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. | BMJ (Clinical research ed.) 20120101 |
| Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. | Cardiovascular diabetology 20120101 |
| A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. | Pharmacoepidemiology and drug safety 20120101 |
| Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. | Endocrine journal 20120101 |
| Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101 |
| Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation. | Skeletal muscle 20120101 |
| Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. | Journal of medical economics 20120101 |
| Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. | Journal of neuroinflammation 20120101 |
| Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. | Gut and liver 20120101 |
| Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study. | PloS one 20120101 |
| Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. | Diabetology & metabolic syndrome 20120101 |
| Simultaneous Determination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride in Tablets by a Validated UPLC Method. | Scientia pharmaceutica 20120101 |
| Perioperative glucose control in neurosurgical patients. | Anesthesiology research and practice 20120101 |
| Reversible mitral and aortic regurgitation due to pioglitazone. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101 |
| Prioritisation of clinical research by the example of type 2 diabetes: a caregiver-survey on perceived relevance and need for evidence. | PloS one 20120101 |
| The influence of incretin mimetics on cardiovascular risk factors in diabetes. | ISRN endocrinology 20120101 |
| Prescribing gliptins: Enthusiasm should be coupled with caution. | Indian journal of endocrinology and metabolism 20120101 |
| Strategies to reverse endothelial progenitor cell dysfunction in diabetes. | Experimental diabetes research 20120101 |
| Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. | BMC pharmacology 20120101 |
| Successful treatment with clonazepam and pramipexole of a patient with sleep-related eating disorder associated with restless legs syndrome: a case report. | Case reports in medicine 20120101 |
| Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. | PloS one 20120101 |
| Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. | Journal of biomedical semantics 20120101 |
| It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. | Experimental diabetes research 20120101 |
| Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents. | CANNT journal = Journal ACITN 20120101 |
| Uncovering undetected hypoglycemic events. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy? | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. | Vascular health and risk management 20120101 |
| Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. | Experimental diabetes research 20120101 |
| A simple matter of life and death-the trials of postnatal Beta-cell mass regulation. | International journal of endocrinology 20120101 |
| Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. | ISRN endocrinology 20120101 |
| A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy. | Endocrine research 20120101 |
| Red carpeting the newer antidiabetics. | Journal of pharmacology & pharmacotherapeutics 20120101 |
| The management of type 2 diabetic patients with hypoglycaemic agents. | ISRN endocrinology 20120101 |
| Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Hypoglycemia in type 2 diabetes: current controversies and changing practices. | Frontiers in endocrinology 20120101 |
| TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. | Scientific reports 20120101 |
| Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. | Experimental diabetes research 20120101 |
| Pain from a Bullet Lingers on: An Uncommon Case of Lead Toxicity. | Case reports in gastroenterology 20120101 |
| Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. | Current medicinal chemistry 20120101 |
| Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. | Journal of medical economics 20120101 |
| Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. | Internal medicine (Tokyo, Japan) 20120101 |
| Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). | Cardiovascular diabetology 20120101 |
| Simultaneous determination of sitagliptin and metformin in pharmaceutical preparations by capillary zone electrophoresis and its application to human plasma analysis. | Analytical chemistry insights 20120101 |
| The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. | TheScientificWorldJournal 20120101 |
| Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats. | Pharmacology 20120101 |
| Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. | Swiss medical weekly 20120101 |
| Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation. | Scientia pharmaceutica 20120101 |
| Adjunctive sitagliptin therapy in postoperative cardiac surgery patients: a pilot study. | International journal of endocrinology 20120101 |
| The effects of simvastatin on the pharmacokinectics of sitagliptin. | Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 20120101 |
| Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. | BMJ open 20120101 |
| Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. | Journal of nutrition and metabolism 20120101 |
| Impact of diabetes on postinfarction heart failure and left ventricular remodeling. | Current heart failure reports 20111201 |
| Effects of DPP-4 inhibition on cardiac metabolism and function in mice. | Journal of molecular and cellular cardiology 20111201 |
| Optimization of cardiac metabolism in heart failure. | Current pharmaceutical design 20111201 |
| Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. | Transplantation 20111127 |
| [Incretin-based therapy for treating patients with type 2 diabetes]. | Orvosi hetilap 20111127 |
| Sitagliptin and simvastatin (juvisync). | The Medical letter on drugs and therapeutics 20111114 |
| Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. | Diabetes, obesity & metabolism 20111101 |
| Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. | Diabetes technology & therapeutics 20111101 |
| Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. | Progress in biophysics and molecular biology 20111101 |
| Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes. | Diabetes research and clinical practice 20111101 |
| Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. | Xenobiotica; the fate of foreign compounds in biological systems 20111101 |
| The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. | Basic research in cardiology 20111101 |
| The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. | International journal of clinical practice 20111101 |
| Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise. | Prescrire international 20111101 |
| Tolerability of dipeptidyl peptidase-4 inhibitors: a review. | Clinical therapeutics 20111101 |
| Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. | Current medical research and opinion 20111101 |
| Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. | BMB reports 20111101 |
| Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. | Current drug safety 20111101 |
| [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)]. | Drugs of today (Barcelona, Spain : 1998) 20111101 |
| Glucagon-like peptide analogues for type 2 diabetes mellitus. | The Cochrane database of systematic reviews 20111005 |
| Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. | Diabetes technology & therapeutics 20111001 |
| Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. | Diabetic medicine : a journal of the British Diabetic Association 20111001 |
| The efficacy and safety of liraglutide. | International journal of clinical pharmacy 20111001 |
| Evaluation of the interaction between sitagliptin and cyclodextrin derivatives by capillary electrophoresis and nuclear magnetic resonance spectroscopy. | Electrophoresis 20111001 |
| Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. | Diabetes & metabolism journal 20111001 |
| 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A. | Bioorganic & medicinal chemistry 20110915 |
| [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]. | Orvosi hetilap 20110911 |
| DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells. | Biochemical and biophysical research communications 20110909 |
| Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects. | Journal of clinical pharmacology 20110901 |
| Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. | Expert opinion on pharmacotherapy 20110901 |
| A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. | Diabetes, obesity & metabolism 20110901 |
| The metabolic syndrome influences the response to incretin-based therapies. | Acta diabetologica 20110901 |
| Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. | International journal of clinical practice 20110901 |
| Next-generation GLP-1 therapy: an introduction to liraglutide. | Postgraduate medicine 20110901 |
| Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications. | Recent patents on endocrine, metabolic & immune drug discovery 20110901 |
| Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. | Current diabetes reviews 20110901 |
| Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110901 |
| Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
| Emerging role of insulin with incretin therapies for management of type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
| Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
| Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? | Journal of medicinal chemistry 20110825 |
| Development of a molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine. | Talanta 20110815 |
| Merging the best of two worlds: artificial metalloenzymes for enantioselective catalysis. | Chemical communications (Cambridge, England) 20110814 |
| Inhibition of anaphylaxis like reaction and mast cell activation by Sitagliptin. | International immunopharmacology 20110801 |
| DPP-IV inhibitor may affect spermatogenesis. | Diabetes research and clinical practice 20110801 |
| Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. | Endocrinology 20110801 |
| Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. | Surgery 20110801 |
| Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin. | Pancreas 20110801 |
| Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. | Clinical therapeutics 20110801 |
| Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus. | Diabetes & metabolism journal 20110801 |
| Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. | Expert opinion on drug discovery 20110801 |
| Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. | Drugs 20110730 |
| Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. | The Journal of biological chemistry 20110722 |
| Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product. | Talanta 20110715 |
| Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. | Diabetes, obesity & metabolism 20110701 |
| Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. | Gastroenterology 20110701 |
| The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20110701 |
| Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. | Diabetes research and clinical practice 20110701 |
| Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. | Diabetes research and clinical practice 20110701 |
| Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. | Diabetes technology & therapeutics 20110701 |
| Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. | Nature chemical biology 20110701 |
| Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice. | Pancreas 20110701 |
| Sitagliptin: a review. | Expert opinion on pharmacotherapy 20110701 |
| GLP-1-based therapies: the dilemma of uncertainty. | Gastroenterology 20110701 |
| Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. | The Annals of pharmacotherapy 20110701 |
| Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity? | British journal of hospital medicine (London, England : 2005) 20110701 |
| Health economic evaluation of dipeptidyl peptidase-4 inhibitors. | Indian journal of endocrinology and metabolism 20110701 |
| DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. | Diabetic medicine : a journal of the British Diabetic Association 20110601 |
| Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. | Hepatology research : the official journal of the Japan Society of Hepatology 20110601 |
| Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20110601 |
| Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. | Diabetes care 20110601 |
| Use of metformin in the setting of mild-to-moderate renal insufficiency. | Diabetes care 20110601 |
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. | Journal of the American Geriatrics Society 20110601 |
| Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report. | Transplantation proceedings 20110601 |
| Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration. | Diabetes & metabolism journal 20110601 |
| Letter: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65). | Diabetes & metabolism journal 20110601 |
| Response: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65). | Diabetes & metabolism journal 20110601 |
| Place in therapy for liraglutide and saxagliptin for type 2 diabetes. | Southern medical journal 20110601 |
| [Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. | Se pu = Chinese journal of chromatography 20110601 |
| An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. | Contemporary clinical trials 20110501 |
| Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. | Diabetes research and clinical practice 20110501 |
| Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. | Current medical research and opinion 20110501 |
| Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. | Postgraduate medicine 20110501 |
| [Incretin enhancer: sitagliptin]. | Nihon rinsho. Japanese journal of clinical medicine 20110501 |
| [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20110501 |
| Liraglutide for the treatment of type 2 diabetes. | Health technology assessment (Winchester, England) 20110501 |
| Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. | Clinical therapeutics 20110501 |
| Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. | Clinical therapeutics 20110501 |
| Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501 |
| Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501 |
| Journal withdraws article after complaints from drug manufacturers. | BMJ (Clinical research ed.) 20110411 |
| Status of protein engineering for biocatalysts: how to design an industrially useful biocatalyst. | Current opinion in chemical biology 20110401 |
| Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. | Diabetes, obesity & metabolism 20110401 |
| Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20110401 |
| Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20110401 |
| Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. | Analytical and bioanalytical chemistry 20110401 |
| Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. | Diabetes 20110401 |
| One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. | International journal of clinical practice 20110401 |
| [Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care]. | Wiener klinische Wochenschrift 20110401 |
| Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. | Diabetes & metabolism journal 20110401 |
| Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity. | Diabetes & metabolism journal 20110401 |
| Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus. | Diabetes & metabolism journal 20110401 |
| Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. | European journal of pharmacology 20110325 |
| Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors. | Bioorganic & medicinal chemistry letters 20110315 |
| Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes. | Bioorganic & medicinal chemistry letters 20110315 |
| Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. | Journal of hypertension 20110301 |
| Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. | Biological chemistry 20110301 |
| Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers. | Biological chemistry 20110301 |
| Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. | Diabetes, obesity & metabolism 20110301 |
| Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. | British journal of clinical pharmacology 20110301 |
| Sitagliptin and metformin--novel combination therapy. | Expert opinion on pharmacotherapy 20110301 |
| Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. | Bioorganic & medicinal chemistry letters 20110301 |
| Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. | Diabetic medicine : a journal of the British Diabetic Association 20110301 |
| Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats. | Experimental biology and medicine (Maywood, N.J.) 20110301 |
| A diabetes drug, sitagliptin, also has a potential to prevent diabetes. | Experimental biology and medicine (Maywood, N.J.) 20110301 |
| Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110301 |
| Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis. | Angewandte Chemie (International ed. in English) 20110225 |
| Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. | Drugs 20110212 |
| Severe leucopenia associated with Sitagliptin use. | Diabetes research and clinical practice 20110201 |
| Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. | American journal of physiology. Endocrinology and metabolism 20110201 |
| Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. | Endocrinology 20110201 |
| Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. | Diabetes, obesity & metabolism 20110201 |
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. | International journal of clinical practice 20110201 |
| Type 2 diabetes: uses of thiazolidinediones and insulin. | Diabetes care 20110201 |
| Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. | Diabetes care 20110201 |
| Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. | Diabetes care 20110201 |
| Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. | The Tohoku journal of experimental medicine 20110201 |
| Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients. | The Journal of the American Osteopathic Association 20110201 |
| Alogliptin for the treatment of type 2 diabetes. | Drugs of today (Barcelona, Spain : 1998) 20110201 |
| Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. | Hospital practice (1995) 20110201 |
| Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions. | Prescrire international 20110201 |
| Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. | Journal of medicinal chemistry 20110127 |
| Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. | Regulatory peptides 20110117 |
| Advances in the treatment of type 2 diabetes mellitus. | American journal of therapeutics 20110101 |
| Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. | Clinical science (London, England : 1979) 20110101 |
| Weight considerations in pharmacotherapy for type 2 diabetes. | Journal of obesity 20110101 |
| Anti-inflammatory nutrition as a pharmacological approach to treat obesity. | Journal of obesity 20110101 |
| Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. | Diabetes, obesity & metabolism 20110101 |
| Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. | Diabetes technology & therapeutics 20110101 |
| Sitagliptin reduces albuminuria in patients with type 2 diabetes. | Endocrine journal 20110101 |
| Understanding diabetes in patients with HIV/AIDS. | Diabetology & metabolic syndrome 20110101 |
| Rodent models for metabolic syndrome research. | Journal of biomedicine & biotechnology 20110101 |
| Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. | Postgraduate medicine 20110101 |
| Vildagliptin-induced acute pancreatitis. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations' by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83). | Journal of diabetes and its complications 20110101 |
| Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. | Cardiology research and practice 20110101 |
| Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. | Journal of medical case reports 20110101 |
| Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. | BMC endocrine disorders 20110101 |
| A case of drug-induced hepatic injury associated with sitagliptin. | Internal medicine (Tokyo, Japan) 20110101 |
| Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. | Experimental diabetes research 20110101 |
| Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. | PloS one 20110101 |
| Amebic encephalitis. | Surgical neurology international 20110101 |
| Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. | Experimental diabetes research 20110101 |
| Precursor B-cell acute lymphoblastic leukemia presenting as obstructive jaundice: a case report. | Journal of medical case reports 20110101 |
| Diabetes and Ramadan: an update on use of glycemic therapies during fasting. | Annals of Saudi medicine 20110101 |
| Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines. | Indian journal of endocrinology and metabolism 20110101 |
| Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. | Cardiovascular diabetology 20110101 |
| Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. | Experimental diabetes research 20110101 |
| Glucagon-like peptide-1 gene therapy. | Experimental diabetes research 20110101 |
| From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. | Experimental diabetes research 20110101 |
| Electroacupuncture-induced cholinergic nerve activation enhances the hypoglycemic effect of exogenous insulin in a rat model of streptozotocin-induced diabetes. | Experimental diabetes research 20110101 |
| New onset diabetes after transplantation (NODAT): an overview. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. | The open cardiovascular medicine journal 20110101 |
| Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. | Journal of nutrition and metabolism 20110101 |
| Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation. | Diabetology & metabolic syndrome 20110101 |
| Reply to the 'Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'', by Avogaro (Journal of Diabetes and Its Complications 25 [2011] 352-353). | Journal of diabetes and its complications 20110101 |
| Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. | Clinical drug investigation 20110101 |
| Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications. | Experimental diabetes research 20110101 |
| Effects of the Soluble Fiber Complex PolyGlycopleX on Glucose Homeostasis and Body Weight in Young Zucker Diabetic Rats. | Frontiers in pharmacology 20110101 |
| [Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study 'SUGAR']. | Revue medicale de Liege 20110101 |
| Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. | Cardiovascular diabetology 20110101 |
| Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. | The open medicinal chemistry journal 20110101 |
| Valorising and creating access to innovative medicines in the European union. | Frontiers in pharmacology 20110101 |
| Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. | Core evidence 20110101 |
| Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. | Hepato-gastroenterology 20110101 |
| Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. | Indian journal of endocrinology and metabolism 20110101 |
| Choosing a gliptin. | Indian journal of endocrinology and metabolism 20110101 |
| Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. | Open medicine : a peer-reviewed, independent, open-access journal 20110101 |
| Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. | PloS one 20110101 |
| Management of diabetes across the course of disease: minimizing obesity-associated complications. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Functional expression and characterization of dipeptidyl peptidase IV from the black-bellied hornet Vespa basalis in Sf21 insect cells. | Bioscience, biotechnology, and biochemistry 20110101 |
| Development of a nongenetic mouse model of type 2 diabetes. | Experimental diabetes research 20110101 |
| A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. | Cardiovascular diabetology 20110101 |
| Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). | Experimental diabetes research 20110101 |
| Predicting biological functions of compounds based on chemical-chemical interactions. | PloS one 20110101 |
| A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening. | Chemistry (Weinheim an der Bergstrasse, Germany) 20101203 |
| Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study. | Diabetes care 20101201 |
| Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. | Diabetes care 20101201 |
| Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters. | Xenobiotica; the fate of foreign compounds in biological systems 20101201 |
| Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. | Mayo Clinic proceedings 20101201 |
| [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors]. | Drugs of today (Barcelona, Spain : 1998) 20101201 |
| Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. | Korean diabetes journal 20101201 |
| Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201 |
| Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis. | International journal of cardiology 20101119 |
| Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. | Diabetes care 20101101 |
| DPP-4 inhibitors: what may be the clinical differentiators? | Diabetes research and clinical practice 20101101 |
| Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. | European journal of medicinal chemistry 20101101 |
| Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. | Current diabetes reviews 20101101 |
| Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. | International journal of clinical practice 20101101 |
| [Medication of the month. Sitagliptin-metformin fixed combination (Janumet)]. | Revue medicale de Liege 20101101 |
| [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose]. | MMW Fortschritte der Medizin 20101007 |
| SLCO1B1 polymorphism and oral antidiabetic drugs. | Basic & clinical pharmacology & toxicology 20101001 |
| Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. | Hypertension (Dallas, Tex. : 1979) 20101001 |
| Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. | Hypertension (Dallas, Tex. : 1979) 20101001 |
| Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. | Expert opinion on drug metabolism & toxicology 20101001 |
| Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose. | Diabetes research and clinical practice 20101001 |
| Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. | Diabetes/metabolism research and reviews 20101001 |
| American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1. | IDrugs : the investigational drugs journal 20101001 |
| Glycaemic control with liraglutide: the phase 3 trial programme. | International journal of clinical practice. Supplement 20101001 |
| Liraglutide: effects beyond glycaemic control in diabetes treatment. | International journal of clinical practice. Supplement 20101001 |
| Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. | Diabetes, obesity & metabolism 20101001 |
| Sitagliptin-induced hemolysis. | Indian journal of pharmacology 20101001 |
| Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. | The American journal of geriatric pharmacotherapy 20101001 |
| Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. | Journal of medicinal chemistry 20100923 |
| Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. | Clinical pharmacokinetics 20100901 |
| Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go .. | Diabetes care 20100901 |
| Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. | The Journal of family practice 20100901 |
| Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. | The Journal of family practice 20100901 |
| Distinguishing among incretin-based therapies. Patient education and self-management. | The Journal of family practice 20100901 |
| Distinguishing among incretin-based therapies. Introduction. | The Journal of family practice 20100901 |
| Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. | The Journal of family practice 20100901 |
| Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor. | Postgraduate medicine 20100901 |
| [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors]. | Medicina clinica 20100901 |
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. | Lancet (London, England) 20100807 |
| Individualised incretin-based treatment for type 2 diabetes. | Lancet (London, England) 20100807 |
| The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. | Clinical endocrinology 20100801 |
| Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20100801 |
| Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. | Diabetes care 20100801 |
| The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. | Diabetes care 20100801 |
| Managing type 2 diabetes in the primary care setting: beyond glucocentricity. | The American journal of the medical sciences 20100801 |
| Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. | Diabetes, obesity & metabolism 20100801 |
| Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone. | Evidence-based medicine 20100801 |
| Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. | Expert opinion on investigational drugs 20100801 |
| Recommendations for management of diabetes during Ramadan: update 2010. | Diabetes care 20100801 |
| Sitagliptin in treatment of diabetes complicated by chronic hepatitis C. | Hepatobiliary & pancreatic diseases international : HBPD INT 20100801 |
| Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. | The American journal of managed care 20100801 |
| Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. | Indian journal of pharmacology 20100801 |
| A medicinal chemist's guide to molecular interactions. | Journal of medicinal chemistry 20100722 |
| Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. | Science (New York, N.Y.) 20100716 |
| Biochemistry. Reengineering enzymes. | Science (New York, N.Y.) 20100716 |
| Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. | Archives of internal medicine 20100712 |
| Induced-fit mechanism for prolyl endopeptidase. | The Journal of biological chemistry 20100709 |
| The evolving place of incretin-based therapies in type 2 diabetes. | Pediatric nephrology (Berlin, Germany) 20100701 |
| The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. | Diabetes 20100701 |
| Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. | Diabetologia 20100701 |
| Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. | Diabetes care 20100701 |
| The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. | Diabetes care 20100701 |
| Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. | Diabetes 20100701 |
| Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. | Clinical and experimental pharmacology & physiology 20100701 |
| Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. | Current medical research and opinion 20100701 |
| Diabetes and cancer: a consensus report. | Diabetes care 20100701 |
| GIP: an inconsequential incretin or not? | Diabetes care 20100701 |
| Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. | Diabetes, obesity & metabolism 20100701 |
| Determination of sitagliptinin human plasma using protein precipitation and tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100701 |
| Incretin physiology and its role in type 2 diabetes mellitus. | The Journal of the American Osteopathic Association 20100701 |
| Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20100701 |
| [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. | Orvosi hetilap 20100620 |
| (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. | Bioorganic & medicinal chemistry letters 20100615 |
| Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. | Cell metabolism 20100609 |
| Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. | Clinical science (London, England : 1979) 20100608 |
| Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. | Metabolism: clinical and experimental 20100601 |
| Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. | International journal of clinical practice 20100601 |
| Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. | Pharmacotherapy 20100601 |
| Diabesity: therapeutic options. | Diabetes, obesity & metabolism 20100601 |
| The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. | American journal of physiology. Heart and circulatory physiology 20100501 |
| Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. | Diabetes, obesity & metabolism 20100501 |
| Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice. | Diabetes, obesity & metabolism 20100501 |
| Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20100501 |
| Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. | Postgraduate medicine 20100501 |
| Choosing among the incretin agents and why it matters. | The Journal of family practice 20100501 |
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. | Lancet (London, England) 20100424 |
| [New hypoglycemic agents in type 2 diabetes]. | La Revue du praticien 20100420 |
| Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. | Diabetes care 20100401 |
| Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. | Diabetes 20100401 |
| Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. | Current opinion in investigational drugs (London, England : 2000) 20100401 |
| Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. | Diabetes, obesity & metabolism 20100401 |
| Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20100401 |
| Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA. | Evidence-based medicine 20100401 |
| Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. | International journal of clinical practice 20100401 |
| Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. | Advances in therapy 20100401 |
| Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. | Diabetic medicine : a journal of the British Diabetic Association 20100401 |
| Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. | Diabetic medicine : a journal of the British Diabetic Association 20100401 |
| Sitagliptin: too many cases of pancreatitis. | Prescrire international 20100401 |
| Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. | Drugs 20100305 |
| The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. | Diabetologia 20100301 |
| Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. | Experimental gerontology 20100301 |
| Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20100301 |
| DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. | Circulation. Cardiovascular imaging 20100301 |
| Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity. | Diabetes research and clinical practice 20100301 |
| [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. | Pharmazie in unserer Zeit 20100301 |
| Incretin-based therapies: review of current clinical trial data. | The American journal of medicine 20100301 |
| [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus]. | Medizinische Klinik (Munich, Germany : 1983) 20100301 |
| New therapeutic options: management strategies to optimize glycemic control. | The Journal of the American Osteopathic Association 20100301 |
| The physiologic role of incretin hormones: clinical applications. | The Journal of the American Osteopathic Association 20100301 |
| [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. | Revue medicale de Liege 20100301 |
| Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial. | Diabetes care 20100201 |
| Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors. | ChemMedChem 20100201 |
| Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20100201 |
| Incretin concepts. | Diabetes care 20100201 |
| Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. | Diabetes care 20100201 |
| GLP-1-based therapy for diabetes: what you do not know can hurt you. | Diabetes care 20100201 |
| Elevated hepatic enzymes potentially associated with sitagliptin. | The Annals of pharmacotherapy 20100201 |
| [Pharmacovigilance update]. | Revue medicale suisse 20100120 |
| Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. | Journal of diabetes and its complications 20100101 |
| Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101 |
| Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. | Diabetologia 20100101 |
| Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation. | Journal of diabetes and its complications 20100101 |
| Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? | Diabetologia 20100101 |
| The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. | Diabetes technology & therapeutics 20100101 |
| Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects. | Pharmacology 20100101 |
| Do incretin-based therapies cause acute pancreatitis? | Journal of diabetes science and technology 20100101 |
| Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. | Vascular health and risk management 20100101 |
| Clinical approaches to preserve beta-cell function in diabetes. | Advances in experimental medicine and biology 20100101 |
| [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]. | Nederlands tijdschrift voor geneeskunde 20100101 |
| Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. | Endocrine journal 20100101 |
| Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. | BMC endocrine disorders 20100101 |
| Dysglycemias in pregnancy: from diagnosis to treatment. Brazilian consensus statement. | Diabetology & metabolic syndrome 20100101 |
| Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. | Vascular health and risk management 20100101 |
| Rhinorrhea, cough and fatigue in patients taking sitagliptin. | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20100101 |
| Forecasting drug utilization and expenditure in a metropolitan health region. | BMC health services research 20100101 |
| Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. | Endocrine journal 20100101 |
| Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. | PloS one 20100101 |
| Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. | Therapeutics and clinical risk management 20100101 |
| Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. | BMC health services research 20100101 |
| Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. | Diabetology & metabolic syndrome 20100101 |
| Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. | Cardiology in review 20100101 |
| The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. | The Annals of pharmacotherapy 20100101 |
| Sitagliptin intolerance. | Allergologia et immunopathologia 20100101 |
| S28 peptidases: lessons from a seemingly 'dysfunctional' family of two. | BMC biology 20100101 |
| A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. | Pharmacology 20100101 |
| Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. | PloS one 20100101 |
| Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). | Mediators of inflammation 20100101 |
| Living Well with Diabetes: a randomized controlled trial of a telephone-delivered intervention for maintenance of weight loss, physical activity and glycaemic control in adults with type 2 diabetes. | BMC public health 20100101 |
| Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. | PloS one 20100101 |
| Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. | Vascular health and risk management 20100101 |
| Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. | Cardiovascular diabetology 20100101 |
| Exenatide once weekly: clinical outcomes and patient satisfaction. | Patient preference and adherence 20100101 |
| Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. | Vascular health and risk management 20100101 |
| Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. | Clinical drug investigation 20100101 |
| Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. | Core evidence 20100101 |
| Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. | Cardiovascular diabetology 20100101 |
| Liraglutide in the management of type 2 diabetes. | Drug design, development and therapy 20100101 |
| Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. | BMC endocrine disorders 20100101 |
| The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session. | Diabetology & metabolic syndrome 20100101 |
| [The incretin effect and type 2 diabetes]. | Revista medica del Instituto Mexicano del Seguro Social 20100101 |
| Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. | Patient preference and adherence 20100101 |
| Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Optimizing weight control in diabetes: antidiabetic drug selection. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Saxagliptin for type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. | Drug, healthcare and patient safety 20100101 |
| Use of sensors in the treatment and follow-up of patients with diabetes mellitus. | Sensors (Basel, Switzerland) 20100101 |
| Pharmacological management of metabolic syndrome and its lipid complications. | Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20100101 |
| Exercise therapy in type 2 diabetes. | Acta diabetologica 20091201 |
| Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. | Diabetes 20091201 |
| Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. | Gastroenterology 20091201 |
| The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. | Gastroenterology 20091201 |
| The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. | Pharmacotherapy 20091201 |
| Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. | Cleveland Clinic journal of medicine 20091201 |
| Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. | European journal of pharmacology 20091125 |
| Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. | Diabetes, obesity & metabolism 20091101 |
| Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. | Schizophrenia research 20091101 |
| Incretin-based therapies: viewpoints on the way to consensus. | Diabetes care 20091101 |
| Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. | Diabetes care 20091101 |
| Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. | Diabetes care 20091101 |
| Obesity in the elderly diabetic patient: is weight loss beneficial? No. | Diabetes care 20091101 |
| Inventing and understanding catalytic, enantioselective reactions. | Current opinion in drug discovery & development 20091101 |
| DPP-4 inhibitors in clinical practice. | Postgraduate medicine 20091101 |
| A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. | Clinical therapeutics 20091101 |
| [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia]. | MMW Fortschritte der Medizin 20091015 |
| [Combination antidiabetic therapy. Better control of blood glucose values]. | MMW Fortschritte der Medizin 20091015 |
| Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. | Pharmacology & therapeutics 20091001 |
| Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. | Current medical research and opinion 20091001 |
| Pharmacotherapy of hyperglycemia. | Expert opinion on pharmacotherapy 20091001 |
| Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. | Journal of clinical pharmacology 20091001 |
| Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon. | Journal of managed care pharmacy : JMCP 20091001 |
| Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. | Clinical science (London, England : 1979) 20090928 |
| The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. | Diabetes care 20090901 |
| Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. | Diabetes care 20090901 |
| Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. | Diabetes 20090901 |
| Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. | Journal of managed care pharmacy : JMCP 20090901 |
| Defining the importance of daily glycemic control and implications for type 2 diabetes management. | Postgraduate medicine 20090901 |
| Direct asymmetric reductive amination. | Journal of the American Chemical Society 20090819 |
| Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors. | European journal of medicinal chemistry 20090801 |
| Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20090801 |
| Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. | Bioorganic & medicinal chemistry letters 20090801 |
| A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. | Journal of clinical pharmacology 20090801 |
| Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). | Best practice & research. Clinical endocrinology & metabolism 20090801 |
| Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. | Best practice & research. Clinical endocrinology & metabolism 20090801 |
| Dyshidrotic eczema: relevance to the immune response in situ. | North American journal of medical sciences 20090801 |
| Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. | Diabetes care 20090701 |
| Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. | Diabetes 20090701 |
| Highly efficient asymmetric synthesis of sitagliptin. | Journal of the American Chemical Society 20090701 |
| Functional assessment of pancreatic beta-cell area in humans. | Diabetes 20090701 |
| Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. | Diabetic medicine : a journal of the British Diabetic Association 20090701 |
| Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. | European journal of internal medicine 20090701 |
| Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. | The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20090601 |
| Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. | The American journal of medicine 20090601 |
| CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. | Journal of enzyme inhibition and medicinal chemistry 20090601 |
| Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. | Prescrire international 20090601 |
| Sitagliptin: serious allergies. Risks greater than benefits. | Prescrire international 20090601 |
| Initial therapy for type 2 diabetes. Examination of a combination approach. | Advance for nurse practitioners 20090601 |
| [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths]. | MMW Fortschritte der Medizin 20090507 |
| GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. | Diabetes 20090501 |
| Impact of sitagliptin on markers of beta-cell function: a meta-analysis. | The American journal of the medical sciences 20090501 |
| [The value of incretin based therapies]. | Deutsche medizinische Wochenschrift (1946) 20090501 |
| Incretin-based therapies for type 2 diabetes mellitus. | Nature reviews. Endocrinology 20090501 |
| By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I be getting more aggressive in my treatment? | Harvard health letter 20090501 |
| C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. | JAMA 20090415 |
| [Incretin related agents for treatment of diabetes mellitus]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410 |
| Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. | Journal of medicinal chemistry 20090409 |
| Effect of sitagliptin on the pharmacokinetics of simvastatin. | Journal of clinical pharmacology 20090401 |
| Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors. | Bioorganic & medicinal chemistry letters 20090401 |
| Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. | Current medical research and opinion 20090401 |
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. | Diabetes 20090401 |
| Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors. | Bioorganic & medicinal chemistry 20090315 |
| New treatments in type 2 diabetes: a focus on the incretin-based therapies. | Clinical endocrinology 20090301 |
| Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. | Diabetes 20090301 |
| Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. | Bioorganic & medicinal chemistry 20090301 |
| Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. | Current medical research and opinion 20090301 |
| Diabetes treatment. | Diabetes care 20090301 |
| Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. | Pharmacotherapy 20090301 |
| Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090301 |
| DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. | Advances in therapy 20090301 |
| Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes. | American family physician 20090301 |
| Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). | Diabetic medicine : a journal of the British Diabetic Association 20090301 |
| Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. | Advances in therapy 20090301 |
| Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. | Advances in therapy 20090201 |
| Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1). | Diabetic medicine : a journal of the British Diabetic Association 20090201 |
| Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? | Diabetic medicine : a journal of the British Diabetic Association 20090201 |
| Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. | Current drug metabolism 20090201 |
| Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable. | Prescrire international 20090201 |
| Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure. | Leukemia research 20090101 |
| Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. | Endocrinology 20090101 |
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. | Diabetes care 20090101 |
| Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. | Diabetes care 20090101 |
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. | Diabetes care 20090101 |
| Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. | Diabetes research and clinical practice 20090101 |
| Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. | Current drug targets 20090101 |
| Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. | Postgraduate medicine 20090101 |
| Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. | Postgraduate medicine 20090101 |
| Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. | Mymensingh medical journal : MMJ 20090101 |
| The therapeutic role of incretin mimetics and DPP-4 inhibitors. | The Diabetes educator 20090101 |
| Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. | The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20090101 |
| Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. | BMC immunology 20090101 |
| Postprandial hyperglycemia as an etiological factor in vascular failure. | Cardiovascular diabetology 20090101 |
| Challenging issues in molecular-targeted therapy. | Therapeutics and clinical risk management 20090101 |
| Potential of liraglutide in the treatment of patients with type 2 diabetes. | Vascular health and risk management 20090101 |
| I read about a new drug for diabetes called Januvia. Should I be interested in it? | Heart advisor 20090101 |
| Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. | PloS one 20090101 |
| Management of progressive type 2 diabetes: role of insulin therapy. | Osteopathic medicine and primary care 20090101 |
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | Cardiovascular diabetology 20090101 |
| Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. | Current medicinal chemistry 20090101 |
| Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. | Therapeutics and clinical risk management 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. | Journal of the American Pharmacists Association : JAPhA 20090101 |
| Efficacy and safety of incretin based therapies: clinical trial data. | Journal of the American Pharmacists Association : JAPhA 20090101 |
| Diabetic nephropathy. | Diabetology & metabolic syndrome 20090101 |
| Stem cell transplantation for type 1 diabetes mellitus. | Diabetology & metabolic syndrome 20090101 |
| Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials. | Diabetology & metabolic syndrome 20090101 |
| Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. | Pharmacological reports : PR 20090101 |
| A patient presenting with symptomatic hypomagnesemia caused by metformin-induced diarrhoea: a case report. | Cases journal 20090101 |
| Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. | Journal of diabetes science and technology 20090101 |
| Gliptins: a new class of oral antidiabetic agents. | Indian journal of pharmaceutical sciences 20090101 |
| Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. | Journal of the American Society of Hypertension : JASH 20090101 |
| Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Alogliptin: a new addition to the class of DPP-4 inhibitors. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| DPP4 inhibitors for diabetes--what next? | Biochemical pharmacology 20081215 |
| Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors. | Bioorganic & medicinal chemistry letters 20081215 |
| Incretin-based therapies in type 2 diabetes: a review of clinical results. | Diabetes research and clinical practice 20081215 |
| Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. | Diabetes, obesity & metabolism 20081201 |
| Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats. | Basic & clinical pharmacology & toxicology 20081201 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. | Diabetes care 20081201 |
| Effects of antidiabetic drugs on glucose tolerance in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20081201 |
| Management of type 2 diabetes in patients with heart failure. | Current treatment options in cardiovascular medicine 20081201 |
| Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. | Expert opinion on emerging drugs 20081201 |
| The role of incretins in glucose homeostasis and diabetes treatment. | Pharmacological reviews 20081201 |
| Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. | Acta bio-medica : Atenei Parmensis 20081201 |
| Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. | Vascular health and risk management 20081201 |
| Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. | Vascular health and risk management 20081201 |
| Vildagliptin: a new oral treatment for type 2 diabetes mellitus. | Vascular health and risk management 20081201 |
| Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. | Cardiology clinics 20081101 |
| The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. | Current diabetes reviews 20081101 |
| [Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1]. | MMW Fortschritte der Medizin 20081030 |
| National trends in treatment of type 2 diabetes mellitus, 1994-2007. | Archives of internal medicine 20081027 |
| Incretin-based therapies in type 2 diabetes mellitus. | The Journal of clinical endocrinology and metabolism 20081001 |
| Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. | Current medical research and opinion 20081001 |
| Janumet: a combination product suitable for use in patients with Type 2 diabetes. | Expert opinion on investigational drugs 20081001 |
| [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?]. | Deutsche medizinische Wochenschrift (1946) 20081001 |
| [Sitagliptin]. | Revue de l'infirmiere 20081001 |
| Recent advances in the management of type 2 diabetes mellitus: a review. | Postgraduate medical journal 20081001 |
| Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. | Diabetic medicine : a journal of the British Diabetic Association 20081001 |
| Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes. | Prescrire international 20081001 |
| Natural products as inspiration for the development of asymmetric catalysis. | Nature 20080918 |
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20080901 |
| Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors. | European journal of medicinal chemistry 20080901 |
| A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. | European journal of medicinal chemistry 20080801 |
| Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. | Diabetes care 20080801 |
| PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. | Diabetes 20080801 |
| Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. | Diabetes 20080801 |
| Approaches to treatment of type 2 diabetes. | Diabetes care 20080801 |
| Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. | Arquivos brasileiros de endocrinologia e metabologia 20080801 |
| RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20080801 |
| New combination treatments in the management of diabetes: focus on sitagliptin-metformin. | Vascular health and risk management 20080801 |
| Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. | Vascular health and risk management 20080801 |
| [New drugs; exenatide and sitagliptin]. | Nederlands tijdschrift voor geneeskunde 20080726 |
| Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. | Bioorganic & medicinal chemistry letters 20080715 |
| Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. | British journal of clinical pharmacology 20080701 |
| Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. | Diabetes, obesity & metabolism 20080701 |
| Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. | Current opinion in clinical nutrition and metabolic care 20080701 |
| Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. | Expert opinion on pharmacotherapy 20080701 |
| Beyond insulin replacement: addressing the additional needs of the diabetes patient. | Diabetes, obesity & metabolism 20080701 |
| Drugs for type 2 diabetes. | Treatment guidelines from the Medical Letter 20080701 |
| From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. | Current opinion in drug discovery & development 20080701 |
| Three new drugs for type 2 diabetes. | Drug and therapeutics bulletin 20080701 |
| DPP4 inhibitors: a new approach in diabetes treatment. | Advances in therapy 20080701 |
| Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. | Diabetes, obesity & metabolism 20080601 |
| Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. | Hypertension (Dallas, Tex. : 1979) 20080601 |
| Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. | Expert opinion on investigational drugs 20080601 |
| New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. | Expert opinion on pharmacotherapy 20080601 |
| Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. | The AAPS journal 20080601 |
| Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. | Vascular health and risk management 20080601 |
| Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. | Core evidence 20080601 |
| A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. | Endocrinology 20080501 |
| Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. | Diabetes 20080501 |
| Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. | Journal of clinical pharmacology 20080501 |
| Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? | Naunyn-Schmiedeberg's archives of pharmacology 20080501 |
| Managed care perspective on three new agents for type 2 diabetes. | Journal of managed care pharmacy : JMCP 20080501 |
| Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. | Frontiers in bioscience : a journal and virtual library 20080501 |
| Reducing global cardiovascular risk in patients with type 2 diabetes mellitus. | The Journal of the American Osteopathic Association 20080501 |
| Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss. | The Journal of the American Osteopathic Association 20080501 |
| Treating Hispanic patients for type 2 diabetes mellitus: special considerations. | The Journal of the American Osteopathic Association 20080501 |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. | The Cochrane database of systematic reviews 20080416 |
| [New drugs; exenatide and sitagliptin]. | Nederlands tijdschrift voor geneeskunde 20080412 |
| (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. | The Journal of pharmacology and experimental therapeutics 20080401 |
| New drug update: 2007. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401 |
| Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. | Clinical therapeutics 20080401 |
| Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. | Vascular health and risk management 20080401 |
| [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge]. | Lakartidningen 20080401 |
| What's new in clinical pharmacology and therapeutics. | WMJ : official publication of the State Medical Society of Wisconsin 20080401 |
| Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080315 |
| Hypoglycaemia in Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20080301 |
| Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery. | The AAPS journal 20080301 |
| [Sitagliptine (Januvia)]. | Journal de pharmacie de Belgique 20080301 |
| Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20080213 |
| Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. | Diabetes research and clinical practice 20080201 |
| Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. | Biomedical chromatography : BMC 20080201 |
| Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. | Current medical research and opinion 20080201 |
| Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. | Current medical research and opinion 20080201 |
| Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks. | Prescrire international 20080201 |
| [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]. | Revue medicale de Liege 20080201 |
| [Treatment with new preparations against type 2 diabetes not sufficiently documented]. | Lakartidningen 20080201 |
| Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. | Diabetes & metabolism 20080201 |
| How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment. | Bone marrow transplantation 20080101 |
| Dipeptidyl peptidase IV inhibitors and diabetes therapy. | Frontiers in bioscience : a journal and virtual library 20080101 |
| Common crossroads in diabetes management. | Osteopathic medicine and primary care 20080101 |
| Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies. | The Diabetes educator 20080101 |
| History and diagnostic significance of C-peptide. | Experimental diabetes research 20080101 |
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. | Journal of managed care pharmacy : JMCP 20080101 |
| DPP-4 inhibitors. A new class of drugs for type 2 diabetes. | Diabetes self-management 20080101 |
| Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. | Medscape journal of medicine 20080101 |
| Vaccination against GIP for the treatment of obesity. | PloS one 20080101 |
| Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. | The review of diabetic studies : RDS 20080101 |
| New drugs for type 2 diabetes mellitus: what is their place in therapy? | Drugs 20080101 |
| New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. | Drugs & aging 20080101 |
| Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. | BMC endocrine disorders 20080101 |
| What can we learn from drug marketing efficiency? | BMJ (Clinical research ed.) 20080101 |
| New therapeutic approaches in type 2 diabetes. | Acta clinica Belgica 20080101 |
| The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus. | Indian journal of pharmacology 20080101 |
| Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy. | Clinical medicine. Pathology 20080101 |
| Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. | Bioorganic & medicinal chemistry letters 20071215 |
| Unlocking the potential of asymmetric hydrogenation at Merck. | Accounts of chemical research 20071201 |
| DPP-4 inhibitors. | Best practice & research. Clinical endocrinology & metabolism 20071201 |
| Inhaled insulin for controlling blood glucose in patients with diabetes. | Vascular health and risk management 20071201 |
| Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. | Clinical therapeutics 20071201 |
| Clinical management strategies for type 2 diabetes. | JAAPA : official journal of the American Academy of Physician Assistants 20071201 |
| New treatments for type 2 diabetes--the DPP4 inhibitors. | Primary care diabetes 20071201 |
| Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. | Bioorganic & medicinal chemistry letters 20071101 |
| Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). | Drugs of today (Barcelona, Spain : 1998) 20071101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071101 |
| Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. | Drugs of today (Barcelona, Spain : 1998) 20071001 |
| [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin]. | Vnitrni lekarstvi 20071001 |
| Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. | Vascular health and risk management 20071001 |
| GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. | Current diabetes reports 20071001 |
| Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. | Biopharmaceutics & drug disposition 20070901 |
| Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. | Biopharmaceutics & drug disposition 20070901 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Diabetes, obesity & metabolism 20070901 |
| Using prandial insulin to achieve glycemic control in type 2 diabetes. | The Journal of family practice 20070901 |
| Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. | Diabetes, obesity & metabolism 20070901 |
| [The incretin effect: a new therapeutic target in type 2 diabetes]. | Revue medicale de Bruxelles 20070901 |
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | Diabetes care 20070801 |
| Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. | International journal of clinical practice. Supplement 20070801 |
| Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. | International journal of clinical practice. Supplement 20070801 |
| Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. | Pharmacotherapy 20070801 |
| Type 2 diabetes drug boom: is newer better? | The Johns Hopkins medical letter health after 50 20070801 |
| Type 2 diabetes: the end of clinical inertia. | Southern medical journal 20070801 |
| [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2]. | Medizinische Monatsschrift fur Pharmazeuten 20070801 |
| The burden of type 2 diabetes: strategies to prevent or delay onset. | Vascular health and risk management 20070801 |
| Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. | Bioorganic & medicinal chemistry letters 20070715 |
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. | JAMA 20070711 |
| Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. | Diabetes care 20070701 |
| [New concepts in the treatment of type 2 diabetes]. | Der Internist 20070701 |
| A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. | Current medical research and opinion 20070701 |
| New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease. | Heart advisor 20070701 |
| Management of comorbid diabetes and cancer. | Oncology (Williston Park, N.Y.) 20070701 |
| Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. | Bioorganic & medicinal chemistry letters 20070615 |
| Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). | Bioorganic & medicinal chemistry letters 20070615 |
| Sitagliptin/metformin (Janumet) for type 2 diabetes. | The Medical letter on drugs and therapeutics 20070604 |
| Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. | Diabetes care 20070601 |
| Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus? | Nature clinical practice. Endocrinology & metabolism 20070601 |
| Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. | Current medical research and opinion 20070601 |
| Janumet. | JAAPA : official journal of the American Academy of Physician Assistants 20070601 |
| New treatments for diabetes. | The New England journal of medicine 20070524 |
| New treatments for diabetes. | The New England journal of medicine 20070524 |
| New treatments for diabetes. | The New England journal of medicine 20070524 |
| New treatments for diabetes. | The New England journal of medicine 20070524 |
| Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. | The Journal of pharmacology and experimental therapeutics 20070501 |
| Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. | Clinical pharmacology and therapeutics 20070501 |
| Treatment of type 2 diabetes mellitus and the incretin system. | South Dakota medicine : the journal of the South Dakota State Medical Association 20070501 |
| Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. | Drug metabolism and disposition: the biological fate of chemicals 20070401 |
| Characterization of two cyclic metabolites of sitagliptin. | Drug metabolism and disposition: the biological fate of chemicals 20070401 |
| Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. | Drug metabolism and disposition: the biological fate of chemicals 20070401 |
| beta-cell failure in diabetes and preservation by clinical treatment. | Endocrine reviews 20070401 |
| Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. | Expert opinion on investigational drugs 20070401 |
| [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. | Orvosi hetilap 20070401 |
| Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. | Current medical research and opinion 20070401 |
| [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. | Revue medicale de Liege 20070401 |
| Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. | Vascular health and risk management 20070401 |
| Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. | Current opinion in endocrinology, diabetes, and obesity 20070401 |
| Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. | Diabetes, obesity & metabolism 20070301 |
| Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20070301 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Diabetes, obesity & metabolism 20070301 |
| Diabetes drug update: how 4 new options stack up. | The Journal of family practice 20070301 |
| Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. | Journal of clinical pharmacology 20070201 |
| Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. | Journal of clinical pharmacology 20070201 |
| Finding new treatments for diabetes--how many, how fast... how good? | The New England journal of medicine 20070201 |
| Sitagliptin. | Nature reviews. Drug discovery 20070201 |
| Incretins: a new treatment option for type 2 diabetes? | The Netherlands journal of medicine 20070201 |
| (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | Bioorganic & medicinal chemistry letters 20070101 |
| Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | International journal of clinical practice 20070101 |
| Sitagliptin (Januvia) for type 2 diabetes. | The Medical letter on drugs and therapeutics 20070101 |
| The physiology of incretin hormones and the basis for DPP-4 inhibitors. | The Diabetes educator 20070101 |
| Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. | Drugs of today (Barcelona, Spain : 1998) 20070101 |
| Sitagliptin improved glycemic control and beta-cell function in type 2 diabetes. | ACP journal club 20070101 |
| New drugs: sitagliptin phosphate, telbivudine, and panitumumab. | Journal of the American Pharmacists Association : JAPhA 20070101 |
| New treatment for diabetes. | FDA consumer 20070101 |
| Sitagliptin. | Drugs 20070101 |
| Sitagliptin: a viewpoint by Mark S. Kipnes. | Drugs 20070101 |
| Sitagliptin: a viewpoint by Itamar Raz. | Drugs 20070101 |
| Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | Current topics in medicinal chemistry 20070101 |
| [New class of oral antidiabetic drugs. Effective in combination with metformin]. | MMW Fortschritte der Medizin 20070101 |
| Sitagliptin: a novel drug for the treatment of type 2 diabetes. | Cardiology in review 20070101 |
| Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. | Journal of endocrinological investigation 20070101 |
| DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. | The review of diabetic studies : RDS 20070101 |
| First-in-class diabetes drug approved. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061201 |
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | Diabetes care 20061201 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Diabetes care 20061201 |
| Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. | Diabetes & vascular disease research 20061201 |
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. | Lancet (London, England) 20061111 |
| Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20061101 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Diabetologia 20061101 |
| DPP-4 inhibitors and their potential role in the management of type 2 diabetes. | International journal of clinical practice 20061101 |
| Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. | Current medical research and opinion 20061001 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | Clinical therapeutics 20061001 |
| Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. | Experimental biology and medicine (Maywood, N.J.) 20060901 |
| Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. | Geriatrics 20060901 |
| Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. | Journal of clinical pharmacology 20060801 |
| American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA. | IDrugs : the investigational drugs journal 20060801 |
| [DPP-4 inhibition raises incretin levels]. | Medizinische Monatsschrift fur Pharmazeuten 20060801 |
| Therapies for the treatment of type 2 diabetes mellitus based on incretin action. | Minerva endocrinologica 20060601 |
| Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Diabetes 20060601 |
| [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. | Medizinische Monatsschrift fur Pharmazeuten 20060301 |
| Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. | Clinical therapeutics 20060101 |
| Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20060101 |
| Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | The Annals of pharmacotherapy 20060101 |
| The development of a stable, coated pellet formulation of a water-sensitive drug, a case study: development of a stable core formulation. | Pharmaceutical development and technology 20060101 |
| Basic Management of Diabetes Mellitus: Practical guidelines. | The Libyan journal of medicine 20060101 |
| Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. | Clinical pharmacology and therapeutics 20051201 |
| American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors. | IDrugs : the investigational drugs journal 20050801 |
| MK-431 (Merck). | Current opinion in investigational drugs (London, England : 2000) 20050401 |
| (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | Journal of medicinal chemistry 20050113 |
| Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. | Treatments in endocrinology 20050101 |
| New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. | The review of diabetic studies : RDS 20050101 |